Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...

We wanted to price it in India in a way which is comparable to the therapies that are available,' said Vikrant Shrotriya, ...

Novo Nordisk launches Wegovy in India, a once-weekly weight-loss injection shown to aid obesity treatment and reduce heart ...

Wegovy is being made available in five dosing strengths with an easy-to-use pen device, which does away the use of syringes ...

Novo Nordisk ended its partnership with Hims & Hers on 23 June 2025, accusing the telehealth firm of selling unsafe, ...

Novo Nordisk A/S is hunting for more early-stage deals to pad its pipeline of next-generation obesity drugs, as the drugmaker ...

Novo Nordisk drops Hims & Hers because it was selling and promoting a cheaper copycat of Wegovy, its weight loss drug.

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

By Rishika Sadam and Kashish Tandon HYDERABAD (Reuters) -Danish drugmaker Novo Nordisk launched its blockbuster weight-loss ...

Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock is a Hold.

Novo Nordisk, the company behind blockbuster weight-loss drugs like Ozempic and Wegovy, had a deal with Hims & Hers that ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage ...